INVENRA
Invenra is focused on discovering the next generation of best-in-class biologics, with an emphasis on antibodies and their derivatives. The company's proprietary technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of unprecedented numbers of full-length antibodies in phenotypic assays. Invenra touts a broad scientific foundation and a team of scientists with deep expertise in key areas ranging from genomics to biochemistry to bioengineering. Their background is well balanced between cutting edge basic research and commercial products and services. The company was established in 2011 and is based in Madison, Wisconsin, United States.
INVENRA
Industry:
Biotechnology Life Science Medical Pharmaceutical
Founded:
2011-01-01
Address:
Madison, Wisconsin, United States
Country:
United States
Website Url:
http://www.invenra.com
Total Employee:
11+
Status:
Active
Contact:
608-441-8319
Total Funding:
27.18 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Current Advisors List
Current Employees Featured
Founder
Investors List
Venture Investors
Venture Investors investment in Series B - Invenra
NEW Capital Fund
NEW Capital Fund investment in Venture Round - Invenra
Wisconsin Investment Partners
Wisconsin Investment Partners investment in Venture Round - Invenra
Rose Ventures
Rose Ventures investment in Venture Round - Invenra
Madison Development Corporation
Madison Development Corporation investment in Venture Round - Invenra
NEW Capital Fund
NEW Capital Fund investment in Venture Round - Invenra
Wisconsin Investment Partners
Wisconsin Investment Partners investment in Venture Round - Invenra
Venture Management
Venture Management investment in Venture Round - Invenra
Wisconsin Investment Partners
Wisconsin Investment Partners investment in Venture Round - Invenra
NEW Capital Fund
NEW Capital Fund investment in Venture Round - Invenra
Official Site Inspections
http://www.invenra.com Semrush global rank: 4.01 M Semrush visits lastest month: 3.09 K
- Host name: invenra.com-php-8.2-update
- IP address: 64.23.162.22
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Invenra"
About Us - Invenra
Since our founding, we have developed an extensive and proprietary set of platform technologies to enable the discovery and development of novel therapies across a wide range of …See details»
Invenra - Crunchbase Company Profile & Funding
Invenra is focused on discovering the next generation of best-in-class biologics, with an emphasis on antibodies and their derivatives. The company's proprietary technology combines the cell …See details»
Invenra Company Profile 2024: Valuation, Funding
Invenra General Information Description. Developer of a drug discovery platform designed to help discover and optimize human multi-specific antibodies. The company's platform is used to discover and develop new biologic drugs for …See details»
Invenra - LinkedIn
Invenra's proprietary technologies combine our highly developable B-Body™ bispecific platform with high throughput functional screening, enabling the optimization of unprecedented numbers of ...See details»
Invenra Inc. Announces a Strategic Collaboration with Catalent to …
Madison, WI – April 2, 2024 – Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development …See details»
Invenra - Overview, News & Similar companies | ZoomInfo.com
Jan 5, 2022 Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative …See details»
Invenra Company Profile - Office Locations, Competitors ... - Craft
Invenra is a company focused on developing biologics with an emphasis on multispecific antibodies and their derivatives. Its B-Body and SNIPER technologies are used to develop …See details»
Invenra - Products, Competitors, Financials, Employees, …
Invenra primarily engages in development collaborations to advance bispecific antibody programs with partners in the biotechnology and pharmaceutical industries. It was founded in 2011 and …See details»
Invenra Inc. Announces a Strategic Research …
MADISON, Wis., April 09, 2024--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic research agreement with Astellas Pharma, a global ...See details»
Invenra, Inc. Appoints Daniel S. Pereira, Ph.D., as Chief Scientific ...
Jan 5, 2022 Invenra builds out management team to advance immuno-oncology therapeutics pipeline and collaborative discovery efforts MADISON, Wis., Jan 5, 2022 — Invenra, Inc., a …See details»
Invenra Welcomes Three Industry Leaders to Its Board of Directors
Sep 17, 2024 Bryan Glaser Senior Vice President, Business Development Invenra Inc. 608-441-8319 [email protected] Contacts Bryan Glaser Senior Vice President, Business …See details»
Exelixis and Invenra Expand Collaboration to Discover and Develop …
Aug 16, 2021 Under the terms of the original agreement, announced by the parties on May 2, 2018, Exelixis and Invenra are currently collaborating to discover and develop mono-specific …See details»
Invenra, Inc. Appoints Daniel S. Pereira, Ph.D., as Chief Scientific ...
Jan 5, 2022 Invenra builds out management team to advance immuno-oncology therapeutics pipeline and collaborative discovery efforts MADISON, Wis., Jan 5, 2022 -- Invenra, Inc., a …See details»
www.invenra.com Expanding the search for therapeutic antibodies …
Invenra’s head of R&D, Bryan Glaser. Rather than just looking at antibody affinity, Invenra is able to directly interrogate phenotype and resulting biological activity, leading to the selection of the …See details»
Working At Invenra: Company Overview and Culture - Zippia
Invenra Rankings. Invenra is ranked #86 on the Best Health Care Companies to Work For in Wisconsin list. Zippia's Best Places to Work lists provide unbiased, data-based evaluations of …See details»
Invenra, Astellas Launch Partnership Focused on Discovering
Apr 10, 2024 In 2022, Invenra presented data on INV322, an antibody-based cancer therapeutic that was developed through the B-Body platform. 4 “We are very pleased with the strong …See details»
Our Science - Invenra
B-Body: The Premier Bispecific Antibody Platform The B-Body ® Platform is at the core of therapeutic antibody development at Invenra. It is a proven platform for bispecific antibody …See details»
Exelixis fuels $15M into the Invenra research engine, firing up a 20 ...
Aug 16, 2021 Exelixis will pay Invenra $15 million upfront on an expanded collaboration and licensing agreement that includes 20 new oncology targets.. The two companies initially linked …See details»
News - Invenra
Sep 26, 2017 Invenra’s Novel Antibody INV724 Receives Rare Pediatric Disease and Orphan Drug Designations from the US FDA for Neuroblastoma Treatment. August 8, 2024 . Invenra …See details»